June 3, 2022 -- Bioplatform company Flagship Pioneering has unveiled ProFound Therapeutics, founded at Flagship Labs in 2020. The company has committed $75 million to advance the ProFoundry Platform to enable new therapeutic targets and medicines.
The ProFoundry Platform has uncovered tens of thousands of novel proteins, remapping the landscape of the human genome and expanding the number of potential therapeutic targets, according to Flagship Pioneering. The company said the funding will be used toward supporting target discovery efforts and building a robust R&D pipeline.
The ProFoundry Atlas, a database that catalogs tens of thousands of novel proteins and their functionality, connectivity, and roles in health and disease, is at the core of the ProFoundry Platform.
"ProFound is systematically decoding this expanded proteome to understand how these proteins govern biology and enable the development of novel therapeutics across the spectrum of human diseases," said Avak Kahvejian, PhD, Flagship Pioneering general partner and co-founder and CEO of ProFound Therapeutics.
Copyright © 2022 scienceboard.net